<DOC>
	<DOCNO>NCT02211729</DOCNO>
	<brief_summary>The primary objective study determine whether addition azithromycin ( AZ ) Seasonal Malaria Chemoprevention ( SMC ) use sulphadoxine/pyrimethamine ( SP ) +amodiaquine ( AQ ) provide additional reduction death severe illness young African child . The secondary objective include assessment safety cost-effectiveness addition AZ SMC SP+AQ . This double blind , randomise , placebo control trial . The unit randomisation household . Children age 3 - 59 month randomise receive four cycle either SP+AQ+AZ SP+AQ+ placebo monthly interval peak malaria transmission season . Study Sites : Hounde district Burkina Faso Bougouni district , Mali . Children 3-59 month age start period drug administration eligible inclusion trial provide parental consent obtain . Children severe , chronic illness know allergy one study drug exclude . Primary endpoint : Incidence combination death hospital admission least 24 hour , due trauma elective surgery intervention period Secondary endpoint : 1. incidence primary endpoint whole study period 2. attendance study health centre nonmalaria febrile illness 3. attendance study health centre malaria , 4. prevalence moderate anaemia end malaria transmission season , 5. nutritional status end malaria transmission season , 6. prevalence nasopharyngeal carriage pneumococcus macrolide resistant pneumococci end malaria transmission season , 7. prevalence resistance marker SP end study , Sample size : 19,200 child ( 9600 country ) enrol .</brief_summary>
	<brief_title>A Trial Seasonal Malaria Chemoprevention Plus Azithromycin African Children</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<criteria>Children either sex age 359 month age start period drug administration parental consent obtain . severe , chronic illness , know allergy one study drug . HIV+ child cotrimoxazole prophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>